

Claims

1           1.     A method for treating neurotrauma, said method comprising  
2     administering to a subject having neurotrauma a therapeutically effective amount  
3     of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form,  
4     derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

1           2.     A method according to claim 1, wherein the NSAID is intrathecally  
2     delivered.

1           3.     A method according to claim 1, wherein the NSAID is  
2     intraventricularly delivered.

1           4.     A method according to claim 1, wherein the non-steroidal anti-  
2     inflammatory drug comprises choline magnesium trisalicylate. 2189 514/164

1           5.     A method according to claim 1, wherein the non-steroidal anti-  
2     inflammatory drug comprises sodium salicylate. 8515 514/159

1           6.     A method according to claim 1, wherein the non-steroidal anti-  
2     inflammatory drug comprises salicylamide. 8187 514/166

Aspirin 863 514/165  
salicylic acid 8190  
Aspirin 165 /

205150 22261001

1           7.     A method according to claim 1, wherein the non-steroidal anti-  
2     inflammatory drug comprises a deacetylated aspirin.

1           8.     A method of treating diffuse axonal injury, said method comprising  
2     administering to a subject having diffuse axonal injury a therapeutically effective  
3     amount of a naturally occurring omega conotoxin, a functional fragment thereof, a  
4     pharmacologically acceptable salt, ester, amide, or prodrug thereof.

1           9.     A method according to claim 8, wherein the naturally occurring  
2     omega conotoxin, functional fragment thereof, a pharmacologically acceptable  
3     salt, ester, amide, or prodrug thereof is an N-type calcium channel blocker.

1           10.    A method according to claim 8, wherein the naturally occurring  
2     omega conotoxin is selected from the group consisting essentially of GVIA and  
3     MVII.

1           11.    A method according to claim 8, wherein said administering step  
2     further comprises intrathecally delivering the omega conotoxin, functional  
3     fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug  
4     thereof.

205150 2261001

1           12.     A method according to claim 8, wherein said administering step  
2     further comprises intraventricularly delivering the omega conotoxin, functional  
3     fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug  
4     thereof.

1           13.     A method according to claim 8, wherein said administering step  
2     further comprises delivering the omega conotoxin, functional fragment thereof, a  
3     pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject  
4     through an implantable pump.

1           14.     A method according to claim 8, wherein said administering step  
2     further comprises delivering the omega conotoxin, functional fragment thereof, a  
3     pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject  
4     through a spinal catheter.

1           15.     A method according to claim 8, wherein the diffuse axonal injury is  
2     a spastic disorder.

1           16.     A method according to claim 15, wherein the spastic disorder is  
2     caused by traumatic brain injury.

1           17.    A method according to claim 8 further including the step of  
2    administering a non-steroidal anti-inflammatory drug to the subject.

1           18.    A method according to claim 17, wherein the non-steroidal anti-  
2    inflammatory drug comprises choline magnesium trisalicylate.

1           19.    A method according to claim 17, wherein the non-steroidal anti-  
2    inflammatory drug comprises sodium salicylate.

1           20.    A method according to claim 17, wherein the non-steroidal anti-  
2    inflammatory drug comprises salicylamide.

1           21.    A method according to claim 17, wherein the non-steroidal anti-  
2    inflammatory drug comprises a deacetylated aspirin.

1           22.    A method for treating pain, said method comprising administering  
2    to a subject having pain a therapeutically effective amount of a non-steroidal, anti-  
3    inflammatory drug (NSAID), analog, substituted form, derivative, or a  
4    pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

1           23.    A method according to claim 22, wherein the NSAID is  
2    intrathecally delivered.

1           24.    A method according to claim 22, wherein the NSAID is  
2    intraventricularly delivered.

1           25.    A method according to claim 22, wherein the non-steroidal anti-  
2    inflammatory drug comprises choline magnesium trisalicylate.

1           26.    A method according to claim 22, wherein the non-steroidal anti-  
2    inflammatory drug comprises sodium salicylate.

1           27.    A method according to claim 22, wherein the non-steroidal anti-  
2    inflammatory drug comprises salicylamide.

1           28.    A method according to claim 22, wherein the non-steroidal anti-  
2    inflammatory drug comprises a deacetylated aspirin.

1           29.    A method for treating neuronal injury said method comprising  
2    intrathecally administering to a subject having neuronal injury a therapeutically  
3    effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog,  
4    (substituted form)(derivative), or a pharmaceutically acceptable salt, ester, amide, or  
5    prodrug thereof.

(112 P 2)  
what is  
claim?

20010501 2200001

1           30.    A method according to claim 29, wherein the NSAID is  
2    intraventricularly delivered.

1           31.    A method according to claim 29, wherein the non-steroidal anti-  
2    inflammatory drug comprises choline magnesium trisalicylate.

1           32.    A method according to claim 29, wherein the non-steroidal anti-  
2    inflammatory drug comprises sodium salicylate.

1           33.    A method according to claim 29, wherein the non-steroidal anti-  
2    inflammatory drug comprises salicylamide.

1           34.    A method according to claim 29, wherein the non-steroidal anti-  
2    inflammatory drug comprises a deacetylated aspirin.

1           35.    A method according to claim 29, wherein the neuronal injury is  
2    caused by Lupus, inflammatory neuropathy, infection, acquired disorders,  
3    transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.

-112#1+2

205750 2264001